| Dr Mohammad Farooq Ali, MD | |
|
242 Indian Lake Blvd, Suite 100, Hendersonville, TN 37075-6213 | |
| (615) 822-5660 | |
| (615) 822-5611 |
| Full Name | Dr Mohammad Farooq Ali |
|---|---|
| Gender | Male |
| Speciality | Rheumatology |
| Experience | 27 Years |
| Location | 242 Indian Lake Blvd, Hendersonville, Tennessee |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1871696096 | NPI | - | NPPES |
| I24961 | Other | TN | HEALTHSPRING |
| 01043555 | Other | TN | AMERIGROUP |
| TN0103 | Other | TN | AMERICHOICE |
| 3735499 | Medicaid | TN | |
| 4141539 | Other | TN | BCBS |
| 3828504 | Other | TN | MEDICARE |
| 7703883 | Other | TN | AETNA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RR0500X | Internal Medicine - Rheumatology | 41422 (Tennessee) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Macon Community Hospital | Lafayette, TN | Hospital |
| Tristar Hendersonville Medical Center | Hendersonville, TN | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Comprehensive Rheumatology Care Pllc | 7113929894 | 3 |
News Archive
Idera Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing a novel therapeutic approach for the treatment of autoimmune diseases and genetically defined forms of B-cell lymphoma, today announced that enrollment is open for a Phase 1/2 clinical trial of IMO-8400 in patients with Waldenström's macroglobulinemia, following acceptance of its Investigational New Drug application by the U.S. Food and Drug Administration.
New research suggests that people without dementia who begin reporting memory issues may be more likely to develop dementia later, even if they have no clinical signs of the disease.
The Associated Press reports the president needs breakthroughs on three fronts: the cancellations and technology messes and the crisis in confidence among his own supporters. Meanwhile, The Wall Street Journal reports the White House is probing how the rollout flopped despite what they had believed was sufficient planning.
A clinical trial with 149 patients suffering from the very disabling autoimmune disease systemic lupus erythematosus, has shown the effectiveness of a synthetic peptide developed by a team of researchers led by CNRS biologist Slyviane Muller at the Institut de Biologie Moleculaire (IBMC) in Strasbourg, France.
Rheumatoid arthritis patients treated with biologic response modifiers for at least 6 months do not have a greater risk for malignancy than those given other disease-modifying drugs or placebo, conclude US and Spanish researchers.
› Verified 5 days ago
| Entity Name | Comprehensive Rheumatology Care Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1619063542 PECOS PAC ID: 7113929894 Enrollment ID: O20070208000541 |
News Archive
Idera Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing a novel therapeutic approach for the treatment of autoimmune diseases and genetically defined forms of B-cell lymphoma, today announced that enrollment is open for a Phase 1/2 clinical trial of IMO-8400 in patients with Waldenström's macroglobulinemia, following acceptance of its Investigational New Drug application by the U.S. Food and Drug Administration.
New research suggests that people without dementia who begin reporting memory issues may be more likely to develop dementia later, even if they have no clinical signs of the disease.
The Associated Press reports the president needs breakthroughs on three fronts: the cancellations and technology messes and the crisis in confidence among his own supporters. Meanwhile, The Wall Street Journal reports the White House is probing how the rollout flopped despite what they had believed was sufficient planning.
A clinical trial with 149 patients suffering from the very disabling autoimmune disease systemic lupus erythematosus, has shown the effectiveness of a synthetic peptide developed by a team of researchers led by CNRS biologist Slyviane Muller at the Institut de Biologie Moleculaire (IBMC) in Strasbourg, France.
Rheumatoid arthritis patients treated with biologic response modifiers for at least 6 months do not have a greater risk for malignancy than those given other disease-modifying drugs or placebo, conclude US and Spanish researchers.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Mohammad Farooq Ali, MD 353 New Shackle Island Rd, Suite 201a, Hendersonville, TN 37075-2379 Ph: (615) 822-5660 | Dr Mohammad Farooq Ali, MD 242 Indian Lake Blvd, Suite 100, Hendersonville, TN 37075-6213 Ph: (615) 822-5660 |
News Archive
Idera Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing a novel therapeutic approach for the treatment of autoimmune diseases and genetically defined forms of B-cell lymphoma, today announced that enrollment is open for a Phase 1/2 clinical trial of IMO-8400 in patients with Waldenström's macroglobulinemia, following acceptance of its Investigational New Drug application by the U.S. Food and Drug Administration.
New research suggests that people without dementia who begin reporting memory issues may be more likely to develop dementia later, even if they have no clinical signs of the disease.
The Associated Press reports the president needs breakthroughs on three fronts: the cancellations and technology messes and the crisis in confidence among his own supporters. Meanwhile, The Wall Street Journal reports the White House is probing how the rollout flopped despite what they had believed was sufficient planning.
A clinical trial with 149 patients suffering from the very disabling autoimmune disease systemic lupus erythematosus, has shown the effectiveness of a synthetic peptide developed by a team of researchers led by CNRS biologist Slyviane Muller at the Institut de Biologie Moleculaire (IBMC) in Strasbourg, France.
Rheumatoid arthritis patients treated with biologic response modifiers for at least 6 months do not have a greater risk for malignancy than those given other disease-modifying drugs or placebo, conclude US and Spanish researchers.
› Verified 5 days ago
Dr. Disha Awasthi, MD Rheumatology Medicare: Accepting Medicare Assignments Practice Location: 102 Wessington Pl, Hendersonville, TN 37075 Phone: 615-822-2214 Fax: 615-822-6519 | |
Mosunmola Adeshewa Adebowale Ademosu, MD Rheumatology Medicare: Accepting Medicare Assignments Practice Location: 355 New Shackle Island Rd, Hendersonville, TN 37075 Phone: 615-338-1000 | |
Hailu T Kabtimer, MD Rheumatology Medicare: Not Enrolled in Medicare Practice Location: 919 W Main St M3, Hendersonville, TN 37075 Phone: 615-826-2102 Fax: 615-826-2743 | |
Mr. Scott Alan Hande, MD Rheumatology Medicare: Accepting Medicare Assignments Practice Location: 107 Glen Oak Blvd, Suite 202, Hendersonville, TN 37075 Phone: 615-826-0710 Fax: 615-826-0910 | |
Jung H. Lee, M.D. Rheumatology Medicare: Accepting Medicare Assignments Practice Location: 353 New Shackle Island Rd, #300c, Hendersonville, TN 37075 Phone: 615-338-3337 Fax: 615-338-3329 | |
Dr. Marshall R Johnson Jr., MD Rheumatology Medicare: Accepting Medicare Assignments Practice Location: 355 New Shackle Island Rd, Hendersonville, TN 37075 Phone: 615-338-1000 Fax: 615-338-1101 | |
Paul S Daugherty, MD Rheumatology Medicare: Not Enrolled in Medicare Practice Location: 107 Imperial Blvd, Suite 5, Hendersonville, TN 37075 Phone: 615-826-3111 Fax: 615-826-3112 |